China's volume-based procurement policy and US tariffs have forced companies with large business in China to reset their ...

The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...

Diagnostics revenue totaled €1.06 billion in Q3 compared to €1.11 billion a year ago, down 4 percent or a fraction of a percent on an adjusted basis.

The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

The 15-minute digital lateral flow immunoassay originally obtained Emergency Use Authorization from the US FDA in 2020.

The company's platform combines microfluidics, cytology, and artificial intelligence-based image analysis for the identification of mild-to-severe dysplasia.

Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.

The test, which Santa Maria, California-based Hardy distributes in the US under a license from NG Biotech, is designed to detect CTX-M enzymes.

The company reported difficulties ahead for its immunodiagnostics business in China in the wake of changes in late April related to the country's Diagnosis-Related Groups (DRG) policy on hospital lab ...